Abstract
Three years after measles, mumps, and rubella revaccination in 38 human immunodeficiency virus-infected children who had achieved immune recovery after antiretroviral therapy, the prevalence of protective antibody levels was 85% for measles, 61% for mumps, and 79% for rubella, compared with 88%, 84%, and 100%, respectively, 1 month after revaccination.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-HIV Agents / therapeutic use
-
Antibodies, Viral / blood*
-
Antiretroviral Therapy, Highly Active
-
Child
-
Child, Preschool
-
Female
-
HIV Infections / drug therapy*
-
HIV Infections / immunology*
-
Humans
-
Immunization, Secondary*
-
Infant
-
Male
-
Measles / immunology*
-
Mumps / immunology*
-
Rubella / immunology*
-
Time Factors
Substances
-
Anti-HIV Agents
-
Antibodies, Viral